Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qinghong Han

Showing results (101-110 of 143) with videos related to

Pageof 15
Sort By:
Cancer Diagnosis & Prognosis|January 6, 2025
Elevated-c-MYC-expressing Fibrosarcoma Cells With Acquired Gemcitabine Resistance Remain Sensitive to Recombinant Methioninase: A Potential Clinical Strategy for a Recalcitrant DiseaseSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|December 3, 2024
Selective Synergy of Recombinant Methioninase Plus Docetaxel Against Docetaxel-resistant and -sensitive Fibrosarcoma Cells Compared to Normal FibroblastsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|October 30, 2024
Recombinant Methioninase Synergistically Reverses High-docetaxel Resistance Developed in Osteosarcoma CellsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|May 2, 2020
Oral Recombinant Methioninase Inhibits Diabetes Onset in Mice on a High-fat DietYoshihiko Tashiro, Qinghong Han, Yuying Tan, et al.
Biochemical and Biophysical Research Communications|December 31, 2022
Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancerMasuyo Miyake, Kentaro Miyake, Qinghong Han, et al.
Frontiers in Oncology|November 21, 2022
Reversion of methionine addiction of osteosarcoma cells to methionine independence results in loss of malignancy, modulation of the epithelial-mesenchymal phenotype and alteration of histone-H3 lysine-methylationYusuke Aoki, Qinghong Han, Yasunori Tome, et al.
Anticancer Research|January 31, 2025
Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose IvermectinSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Cancer Genomics & Proteomics|October 28, 2024
Extensive DNA Damage and Loss of Cell Viability Occur Synergistically With the Combination of Recombinant Methioninase and Paclitaxel on Pancreatic Cancer Cells which Report DNA-Damage Response in Real TimeSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Biochemical and Biophysical Research Communications|December 17, 2019
Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse modelTakashi Higuchi, Qinghong Han, Kentaro Miyake, et al.
Anticancer Research|August 28, 2024
Overcoming High Trabectedin Resistance of Soft-tissue Sarcoma With Recombinant Methioninase: A Potential Solution of a Recalcitrant Clinical ProblemSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Pageof 15

Showing results (101-110 of 143) with videos related to

Sort By:
Pageof 15
Cancer Diagnosis & Prognosis|January 6, 2025
Elevated-c-MYC-expressing Fibrosarcoma Cells With Acquired Gemcitabine Resistance Remain Sensitive to Recombinant Methioninase: A Potential Clinical Strategy for a Recalcitrant DiseaseSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|December 3, 2024
Selective Synergy of Recombinant Methioninase Plus Docetaxel Against Docetaxel-resistant and -sensitive Fibrosarcoma Cells Compared to Normal FibroblastsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|October 30, 2024
Recombinant Methioninase Synergistically Reverses High-docetaxel Resistance Developed in Osteosarcoma CellsSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|May 2, 2020
Oral Recombinant Methioninase Inhibits Diabetes Onset in Mice on a High-fat DietYoshihiko Tashiro, Qinghong Han, Yuying Tan, et al.
Biochemical and Biophysical Research Communications|December 31, 2022
Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancerMasuyo Miyake, Kentaro Miyake, Qinghong Han, et al.
Frontiers in Oncology|November 21, 2022
Reversion of methionine addiction of osteosarcoma cells to methionine independence results in loss of malignancy, modulation of the epithelial-mesenchymal phenotype and alteration of histone-H3 lysine-methylationYusuke Aoki, Qinghong Han, Yasunori Tome, et al.
Anticancer Research|January 31, 2025
Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose IvermectinSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Cancer Genomics & Proteomics|October 28, 2024
Extensive DNA Damage and Loss of Cell Viability Occur Synergistically With the Combination of Recombinant Methioninase and Paclitaxel on Pancreatic Cancer Cells which Report DNA-Damage Response in Real TimeSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Biochemical and Biophysical Research Communications|December 17, 2019
Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse modelTakashi Higuchi, Qinghong Han, Kentaro Miyake, et al.
Anticancer Research|August 28, 2024
Overcoming High Trabectedin Resistance of Soft-tissue Sarcoma With Recombinant Methioninase: A Potential Solution of a Recalcitrant Clinical ProblemSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Pageof 15